20 miliardi di euro l’anno: i costi per il cancro in Italia – Prevenzione attiva, la vera arma vincente
The HELIXAFE algorithm is focused on the innovative Cancer Driver Interception concept and is already on the market. Other existing algorithms, such as OncoDrive and OncoImpact, are focused on molecular pathology for the molecular assessment aimed at Cancer Early Detection and precision medicine (target therapies). OncoDrive identifies cancer driver genes from the list of somatic mutations in a cohort of tumors. The concept is based on the fact that most variants in cancer-causing genes are enriched at a few specific loci. OncoImpact is a model-driven approach to integrate omics profiles and to provide patient-specific cancer driver gene predictions, but not the genomic instability gene driver. What is more, the analysis of a single cancer driver has a very low value in terms of prevention, and none in predictive terms. The BIOSCIENCE GENOMICS combined analysis of multiple cancer drivers allows the most detailed profiling ever offered to healthy people aiming at reducing their colorectal cancer risks.
